Nigeria’s largest publicly listed drugmakers are pushing ahead with efforts to surmount the pain of foreign exchange scarcity in a bid to maintain earnings growth, BusinessDay’s findings have shown.
According to data from the Nigerian Exchange Limited, drugmakers such as May & Baker Nigeria Plc, GlaxoSmithKline Consumer Nigeria Plc, and Neimeth International Pharmaceuticals Plc recorded forex gains; Fidson Healthcare Plc reduced its losses by 60 percent, while Morison Industries Plc and Pharma-Deko Plc did not provide any information on forex transaction.
